首页> 外文期刊>The American Journal of Clinical Nutrition: Official Journal of the American Society for Clinical Nutrition >Effect of increasing protein content of human milk fortifier on growth in preterm infants born at <31 wk gestation: a randomized controlled trial.
【24h】

Effect of increasing protein content of human milk fortifier on growth in preterm infants born at <31 wk gestation: a randomized controlled trial.

机译:人乳强化剂蛋白质含量增加对小于31周出生的早产儿生长的影响:一项随机对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Preterm human milk-fed infants often experience suboptimal growth despite the use of human milk fortifier (HMF). The extra protein supplied in fortifiers may be inadequate to meet dietary protein requirements for preterm infants. OBJECTIVE: We assessed the effect of human milk fortified with a higher-protein HMF on growth in preterm infants. DESIGN: This is a randomized controlled trial in 92 preterm infants born at <31 wk gestation who received maternal breast milk that was fortified with HMF containing 1.4 g protein/100 mL (higher-protein group) or 1.0 g protein/100 mL (current practice) until discharge or estimated due date, whichever came first. The HMFs used were isocaloric and differed only in the amount of protein or carbohydrate. Length, weight, and head-circumference gains were assessed over the study duration. RESULTS: Length gains did not differ between the higher- and standard-protein groups (mean difference: 0.06 cm/wk; 95% CI: -0.01, 0.12 cm/wk; P = 0.08). Infants in the higher-protein group achieved a greater weight at study end (mean difference: 220 g; 95% CI: 23, 419 g; P = 0.03). Secondary analyses showed a significant reduction in the proportion of infants who were less than the 10th percentile for length at the study end in the higher-protein group (risk difference: 0.186; 95% CI: 0.370, 0.003; P = 0.047). CONCLUSIONS: A higher protein intake results in less growth faltering in human milk-fed preterm infants. It is possible that a higher-protein fortifier than used in this study is needed. This trial was registered with the Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au/) as ACTRN12606000525583.
机译:背景:尽管使用了人乳强化剂(HMF),但早产人乳喂养的婴儿经常会出现次优生长。强化剂中提供的额外蛋白质可能不足以满足早产婴儿的饮食蛋白质需求。目的:我们评估了强化了高蛋白HMF的母乳对早产儿生长的影响。设计:这是一项随机对照试验,对92名胎龄小于31 wk的早产儿进行了母乳喂养,这些母乳中加入了含有1.4 g蛋白质/ 100 mL(高蛋白质组)或1.0 g蛋白质/ 100mL(目前)的HMF。做法),直到出院或估计的到期日,以先到者为准。使用的HMF是等热量的,仅蛋白质或碳水化合物的量有所不同。在研究期间评估身长,体重和头围增加。结果:高蛋白组和标准蛋白组的长度增加无差异(平均差异:0.06 cm / wk; 95%CI:-0.01,0.12 cm / wk; P = 0.08)。高蛋白组的婴儿在研究结束时体重增加(平均差异:220 g; 95%CI:23、419 g; P = 0.03)。二级分析显示,在高蛋白组中,研究结束时长度小于10%的婴儿比例显着降低(风险差异:0.186; 95%CI:0.370,0.003; P = 0.047)。结论:较高的蛋白质摄入量可以减少人乳喂养的早产儿的生长发育障碍。可能需要比本研究中使用的蛋白质更高的强化剂。该试验已在澳大利亚新西兰临床试验注册中心(http://www.anzctr.org.au/)上注册为ACTRN12606000525583。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号